Dr. Andrew Rudd is the co-founder and CEO of Palm Therapeutics. Dr. Rudd’s career has centered around developing chemical tools to interrogate biological lipids and their roles in health and disease. He received his PhD in chemistry from UC San Diego where he authored eight high-impact papers and was the recipient of several awards, including the Inamori Fellowship, which recognizes one chemistry PhD student each year based on outstanding research performance. During his PhD work, Dr. Rudd developed the first small molecule probes for directly inhibiting protein palmitoylation in cells. In January 2021, Dr. Rudd launched Palm Therapeutics at JLABS San Diego with the mission of developing the first palmitoylation-targeted therapies. He has secured over one million dollars in nondilutive funding from the NIH and serves as the lead PI on two active SBIR grants at Palm. He is also the recent recipient of the 2023 Servier FAST Discovery Award from Servier Laboratories and California Life Sciences.